Strategic Partnerships OncXerna has a history of collaboration with diagnostic and sequencing leaders, including Qiagen and Exact Sciences, signaling a strong openness to co-development and companion diagnostics which creates scalable sales opportunities for diagnostic integration and co-marketing agreements.

Clinical Stage Advantage As a clinical stage precision oncology company with pipeline assets like navicixizumab and bavituximab, there is a clear entry point for sponsored trials, CRO partnerships, and early access programs with pharma partners seeking novel solid tumor therapies.

Biomarker Platform Xerna AI-driven RNA expression biomarker platform positions OncXerna to offer companion diagnostic development services and predictive biomarker testing, enabling bundled deals with biotech and pharma customers pursuing personalized therapy strategies.

Strategic Fundraising With funding of approximately $30M and a lean team, there is potential to engage strategic investors for milestone-driven collaborations, licensing deals, or co-financing of late-stage development as partners look to de-risk early oncology innovations.

Market Niche Focus on solid tumors such as ovarian, triple-negative breast cancer, and colorectal cancer aligns with high-need indications, offering targeted sales pitches to hospital systems, translational oncology programs, and diagnostic labs seeking relevant companion diagnostics.